Carnegie Mellon researchers have proven that widely available earbuds can double as heart-monitoring devices, capturing subtle cardiac activity with near-clinical accuracy and potentially expanding access to long-term, at-home care.

Now, a research team led by Prof. Dr. Kai Wollert, Head of Molecular and Translational Cardiology at the Department of Cardiology and Angiology at Hannover Medical School (MHH), has discovered that a microprotein called BRICK1 plays a key role in this process.

A new study published in Cell from a team of investigators from the Stanford Departments of Urology and Radiation Oncology, in close collaboration with colleagues from Stanford Cancer Institute, offers a powerful new approach: using a non-invasive urine test to determine, at a molecular level, who benefits from additional therapy—and who does not.